CA2574451A1 — D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
Assigned to Boehringer Ingelheim International GmbH · Expires 2006-02-02 · 20y expired
What this patent protects
The invention relates to D-glucopyranosyl phenyl-substituted cyclene of general formula (I), in which: radicals R1 to R6, Z, Cy as well as R7a, R7b, R7c, R7d are defined as in Claim 1. The inventive compounds have an inhibitory effect upon the sodium-dependent glucose co-transpor…
USPTO Abstract
The invention relates to D-glucopyranosyl phenyl-substituted cyclene of general formula (I), in which: radicals R1 to R6, Z, Cy as well as R7a, R7b, R7c, R7d are defined as in Claim 1. The inventive compounds have an inhibitory effect upon the sodium-dependent glucose co-transporter SGLT. The invention also relates to medicaments for treating metabolic diseases.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.